Pictet-Biotech I dy GBP (FUND:B554RF5) - Fund price


Fund Report

Pictet-Biotech I dy GBP

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager Name-
Inception Date10/09/2009
NAV 20/09/2019GBP 639.87
Day Change1.32%
12 Month Yield0.00%
ISINLU0448836352
Dividend FrequencyAnnually
Net Assets (mil) 31/08/20191,057.02 EUR
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time13:00:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge1.00%
Custody ChargeYes
Ongoing Cost1.20%
AMC1.20%
Fund Rebate0.05%

Morningstar Rating™

StarRatingValueLabel_3

Morningstar Sustainability Rating

Below Average

Below Average


Sustainability Rating as of 31/07/2019

Benchmarks

Fund Benchmark

MSCI World NR USD

Morningstar® Benchmark

NASDAQ Biotechnology TR USD

Growth Of 10,000 (GBP) 31/08/2019

How has this security performed
201420152016201720182019
Fund31.7718.02-8.6114.51-9.3018.81
Category38.5413.41-3.9610.29-7.9613.04
Benchmark42.7618.24-6.1811.10-3.2011.53
  • Fund: Pictet-Biotech I dy GBP
  • Category: Sector Equity Biotechnology
  • Benchmark: NASDAQ Biotechnology TR USD
Trailing Returns % (GBP) 20/09/2019
FundCatBmark
YTD17.4213.2811.35
3 Years Annualised5.214.194.06
5 Years Annualised8.847.968.94
10 Years Annualised12.5314.8018.02

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

This compartment aims to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The Compartment will invest at least twothirds of its total assets/total wealth in equities issued by companies operating in this sector. Geographically, the Compartment’s investment universe is not restricted to a particular area (including emerging countries). However, in light of the particularly innovative nature of the pharmaceutical industry in North America and Western Europe, the vast majority of investments will be made in these regions. To capitalise on particularly innovative projects in the pharmaceuticals field, the Biotech Compartment may invest up to 10% of its net assets in Private Equity and/or unlisted securities.

Portfolio Profile31/08/2019

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Style
Top Holdings
NameSector%
IncreaseDecreaseNew since last portfolio
DecreaseGilead Sciences Inc Healthcare8.28
IncreaseVertex Pharmaceuticals Inc Healthcare7.51
IncreaseAmgen Inc Healthcare7.17
DecreaseRegeneron Pharmaceuticals Inc Healthcare4.20
DecreaseBiogen Inc Healthcare4.03
Asset Allocation %
LongShortNet
Stocks96.250.0096.25
Bonds0.000.000.00
Cash4.570.823.75
Other0.000.000.00
Top Stock Regions
Region%
United States91.31
Eurozone3.37
Europe - ex Euro3.11
United Kingdom1.16
Asia - Emerging1.05
Top Stock Sectors
Stock Sector%
Healthcare100.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.